Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04751539
Status:
COMPLETED
Last Update Posted:
2021-05-11
First Post:
2021-01-28
Brief Title:
A Dose-escalation Study of AND017 in Healthy Subjects
Sponsor:
Kind Pharmaceuticals LLC
Organization:
Kind Pharmaceuticals LLC
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Dose-Escalation Study in Healthy Subjects to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AND017 Following Oral Single and Multiple Dose Administration
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I randomized double-blind placebo-controlled dose-escalation study in healthy subjects to evaluate safety tolerability PKs and PDs of AND017 following oral single and multiple dose administration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None